" class="no-js "lang="en-US"> GenScript - Medtech Alert
Friday, April 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
GenScript | Pharmtech Focus

GenScript

About GenScript

GenScript

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform.

GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript’s business operation spans over 100 countries and regions worldwide, with legal entities located in the U.S., Mainland China, Hong Kong, Japan, Singapore, Netherlands and Ireland. GenScript has provided premium, convenient, and reliable products and services for over 100,000 customers.

GenScript has a number of intellectual property rights and technical secrets, including more than 100 patents and over 270 patent applications. As of December 31-st, 2020, GenScript’s products and services have been cited by 52,500 peer-reviewed journal articles worldwide.

Related Story

News

 GenScript Expands Footprint in Singapore to Provide Premium Gene Synthesis Service | MTA

GenScript Expands Footprint in Singapore to Provide Premium Gene Synthesis Service

February 28 2023

GenScript Biotech Corporation, the world’s leading provider of life-science research tools and services, announced the […]

Industry News

 GenScript Partners with Allozymes to Accelerate Protein Discovery and Target Identification | PTF

GenScript Partners with Allozymes to Accelerate Protein Discovery and Target Identification

December 7 2022

GenScript Biotech Corporation, the world’s leading provider of life-science research tools and services, is partnering […]

Diseases

 GenScript and Gladstone-UCSF Institute of Genomic Immunology Collaborate on Groundbreaking Non-Viral Cell Therapy Study | Pharmtech Focus

GenScript and Gladstone-UCSF Institute of Genomic Immunology Collaborate on Groundbreaking Non-Viral Cell Therapy Study

September 23 2022

GenScript USA Inc., the world’s leading life-science research tools and services provider, is collaborating with researchers at […]

Uncategorized

 GenScript and Avectas Team Up to Improve the Non-Viral Cell Therapy Manufacturing Process | Pharmtech Focus

GenScript and Avectas Team Up to Improve the Non-Viral Cell Therapy Manufacturing Process

September 20 2022

GenScript USA Inc., the world’s leading life-science research tools and services provider and Avectas, a cell engineering technology […]

Diseases

 Avacta Announces AffyXell Expands Its Strategic Partnership With GenScript ProBio | Pharmtech Focus

Avacta Announces AffyXell Expands Its Strategic Partnership With GenScript ProBio

May 17 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company developing innovative cancer therapies […]

Equipment

 GenScript Debuts Industry's Highest Throughput DNA Synthesis Platform for Commercial DNA Digital Data Storage | Pharmtech Focus

GenScript Debuts Industry's Highest Throughput DNA Synthesis Platform for Commercial DNA Digital Data Storage

April 14 2022

GenScript USA Inc., the world’s leading life science research tools and services provider, announced today the debut […]